New shot for tough lymphomas shows early promise but trial halted

NCT ID NCT06018129

Terminated Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive lymphomas (Hodgkin and non-Hodgkin) that had returned or stopped responding to standard treatments. The drug was given as a shot under the skin. The main goals were to check safety and find the right dose. The trial was terminated early, so we have limited information on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GEN3017 (a bispecific antibody that targets CD3 and CD30, given as a shot under the skin)
What this could lead to: If successful, this could point toward a new treatment option for people with certain lymphomas that have not responded to other therapies.
What could go wrong: This was a very early (phase 1/2a) trial that was terminated after only 9 participants, so results are limited. The drug may cause serious side effects like cytokine release syndrome or nerve toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSICAL HODGKIN LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

City of Hope Helford Clinical Research Hospital

Duarte, California, 91010, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Peter MacCallum Cancer Institute trading as Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.